In response to the evolving regulatory landscape, the pharmaceutical sector is required to move beyond simple microorganism enumeration. The revised Annex 1 mandates the identification of microorganisms to the species level.
Tentamus Pharma UK, a leading name in pharmaceutical testing within the UK, is excited to present its latest addition to the testing collection - the Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight (MALDI-TOF) mass spectrometer.
This cutting-edge instrument takes centre stage in the pharmaceutical industry, especially following the recent updates to EudraLex Annex 1 (Manufacture of Sterile Products) in August 2023, underscoring the critical need for precise microorganism identification.
Tentamus Pharma UK rises to this challenge with the introduction of MALDI-TOF, offering accuracy in identifying bacteria, yeast, and fungi.
Key Benefits for Clients and Partners:
This advancement ensures pharmaceutical companies meet updated Annex 1 requirements, upholding the highest levels of product integrity.
Milestone in Pharmaceutical Testing:
Tentamus Pharma UK's introduction of the MALDI-TOF mass spectrometer signifies a milestone in pharmaceutical testing. The rapid and accurate identification of microorganisms aligns with the industry's evolving regulatory requirements. With the potential for multiple plates to be tested daily and a steadfast commitment to a 24-hour turnaround time, Tentamus Pharma UK empowers pharmaceutical manufacturers to elevate their quality control processes, delivering safe and reliable products to the market.
For more information, contact Tentamus Pharma UK at HelloUK@tentamus.com or by calling +44 (0) 1332 497 400.
You can also visit our website: https://www.tentamus-pharma.co.uk/
Our team is ready to promptly assist you in harnessing the power of MALDI-TOF for your pharmaceutical testing needs!
Tentamus Pharma UK, a leading name in pharmaceutical testing within the UK, is excited to present its latest addition to the testing collection - the Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight (MALDI-TOF) mass spectrometer.
This cutting-edge instrument takes centre stage in the pharmaceutical industry, especially following the recent updates to EudraLex Annex 1 (Manufacture of Sterile Products) in August 2023, underscoring the critical need for precise microorganism identification.
Tentamus Pharma UK rises to this challenge with the introduction of MALDI-TOF, offering accuracy in identifying bacteria, yeast, and fungi.
Key Benefits for Clients and Partners:
- MALDI-TOF, a sophisticated mass spectrometer, ensures swift and accurate analysis of microorganisms.
- The instrument's capacity allows for the analysis of 95 samples per plate in under one hour.
- Capable of running multiple analysis sessions daily.
- Fast Turnaround Time: 24 hours.
- Committed to excellent customer service and tailored support.
This advancement ensures pharmaceutical companies meet updated Annex 1 requirements, upholding the highest levels of product integrity.
Milestone in Pharmaceutical Testing:
Tentamus Pharma UK's introduction of the MALDI-TOF mass spectrometer signifies a milestone in pharmaceutical testing. The rapid and accurate identification of microorganisms aligns with the industry's evolving regulatory requirements. With the potential for multiple plates to be tested daily and a steadfast commitment to a 24-hour turnaround time, Tentamus Pharma UK empowers pharmaceutical manufacturers to elevate their quality control processes, delivering safe and reliable products to the market.
For more information, contact Tentamus Pharma UK at HelloUK@tentamus.com or by calling +44 (0) 1332 497 400.
You can also visit our website: https://www.tentamus-pharma.co.uk/
Our team is ready to promptly assist you in harnessing the power of MALDI-TOF for your pharmaceutical testing needs!
